Cardiovascular Pharmacogenomics—Implications for Patients With CKD
| Autor: | Darius L. Mason, Larisa H. Cavallari |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
Ticlopidine Genotype Adrenergic beta-Antagonists 030204 cardiovascular system & hematology Article 03 medical and health sciences 0302 clinical medicine Pharmacotherapy Cytochrome P-450 Enzyme System Vitamin K Epoxide Reductases Internal medicine medicine Humans cardiovascular diseases 030212 general & internal medicine Precision Medicine Renal Insufficiency Chronic Risk factor Intensive care medicine Solute Carrier Proteins business.industry Warfarin Anticoagulants Clopidogrel Phenotype Cardiovascular Diseases Pharmacogenetics Nephrology Pharmacogenomics Purinergic P2Y Receptor Antagonists Cardiology Platelet aggregation inhibitor Hydroxymethylglutaryl-CoA Reductase Inhibitors business Immunosuppressive Agents Platelet Aggregation Inhibitors medicine.drug |
| Zdroj: | Advances in Chronic Kidney Disease. 23:82-90 |
| ISSN: | 1548-5595 |
| DOI: | 10.1053/j.ackd.2015.12.001 |
| Popis: | Chronic kidney disease (CKD) is an independent risk factor for cardiovascular disease. Thus, patients with CKD often require treatment with cardiovascular drugs, such as antiplatelet, antihypertensive, anticoagulant, and lipid-lowering agents. There is significant inter-patient variability in response to cardiovascular therapies, which contributes to risk for treatment failure or adverse drug effects. Pharmacogenomics offers the potential to optimize cardiovascular pharmacotherapy and improve outcomes in patients with cardiovascular disease, though data in patients with concomitant CKD are limited. The drugs with the most pharmacogenomic evidence are warfarin, clopidogrel, and statins. There are also accumulating data for genetic contributions to β-blocker response. Guidelines are now available to assist with applying pharmacogenetic test results to optimize warfarin dosing, selection of antiplatelet therapy after percutaneous coronary intervention, and prediction of risk for statin-induced myopathy. Clinical data, such as age, body size, and kidney function have long been used to optimize drug prescribing. An increasing number of institutions are also implementing genetic testing to be considered in the context of important clinical factors to further personalize drug therapy for patients with cardiovascular disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|